Fields of application SafetyTector™ S is a ready-to-use diluent for immunoassays based on saliva or mucosal swab samples. Diluted samples are directly applied to lateral flow assays as flow buffer. Swabs can be extracted directly with SafetyTector™ S. Diluted samples can also be used in other immunoassays such as ELISA. SafetyTector™ S inactivates SARS-CoV-2 and improves the texture of potentially infectious saliva or mucosal swab samples. At a 1:4 dilution, SafetyTector™ S is able to inactivate SARS-CoV-2 in these samples within 1 min1 (For details please refer to the „Letter of Acknowledgement“issued by the Institute of Molecular Virology, University Hospital Ulm).
Instructions for use SafetyTector™ S is ready-to-use. Please shake the buffer thoroughly before use.
Dilution of the specimens: Samples must be diluted in SafetyTector™ S at least 1:4 (1 part sample in 3 parts SafetyTector™ S) and mixed thoroughly. Standards and specimens should be treated strictly the same way. SafetyTector™ S is not suited for long-term storage of specimens.
Lateral flow assays: SafetyTector™ S replaces the dilution buffer, extraction buffer, chase buffer or flow buffer. Saliva must be diluted with at least 3 sample volumes of SafetyTector™ S. Swabs must be incubated in SafetyTector™ S and should be squeezed for optimal sample recovery, if applicable. Volume of SafetyTector™ S must at least be 3 times the maximum capacity of the swab.
Other assay technologies: SafetyTector™ S may also be employed as sample diluent if saliva or mucosal swab samples are analysed by technologies like ELISA, protein arrays, bead assays (e.g. Luminex assays), immuno-PCR, or automated high-throughput immunoassay systems.
Suitability of SafetyTector™ S for a specific assay has to be tested by the user.
For further information please visit www.candor-bioscience.com
文献引用:
I. White et al. (2021). Bifunctional molecules targeting SARS-CoV-2 spike and the polymeric Ig receptor display neutralization activity and mucosal enrichment. In mAbs (Vol. 13, No. 1, p. 1987180). Taylor & Francis. Y. Liu et al. (2021).
Paradoxical Sex-Specific Patterns of Autoantibodies Response to SARS-CoV-2 Infection. Journal of Translational Medicine, 19(1), 1-13. A. Athanasiou et al. (2021).
A novel serum biomarker quintet reveals added prognostic value when combined with standard clinical parameters in prostate cancer patients by predicting biochemical recurrence and adverse pathology. Plos one, 16(11), e0259093. X. T. Zhang et al. (2021).
A competitive ligand-binding assay for the detection of neutralizing antibodies against dostarlimab (TSR-042). AAPS Open, 7(1), 1-14. J. M. Chan et al. (2021).
Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer. Cancer Cell, 39(11), 1479-1496. F. Rüger et al. (2021).
Gold albumin Sandwich Structures for Enhanced Biosensing using Surface Plasmon Resonance. physica status solidi (a). doi.org/10.1002/pssa.202100029 L. He et al. (2021).
The effects of CD148 Q276P/R326Q polymorphisms in A431D epidermoid cancer cell proliferation and epidermal growth factor receptor signaling. Cancer Reports, e1566. B. Henrick et al. (2021).
Bifidobacteria-mediated immune system imprinting early in life. Cell 184(15), 3884-3898.e11.
I. White et al. (2021). Bifunctional molecules targeting SARS-CoV-2 spike and the polymeric Ig receptor display neutralization activity and mucosal enrichment. In mAbs (Vol. 13, No. 1, p. 1987180). Taylor & Francis. Y. Liu et al. (2021).
Paradoxical Sex-Specific Patterns of Autoantibodies Response to SARS-CoV-2 Infection. Journal of Translational Medicine, 19(1), 1-13. A. Athanasiou et al. (2021).
A novel serum biomarker quintet reveals added prognostic value when combined with standard clinical parameters in prostate cancer patients by predicting biochemical recurrence and adverse pathology. Plos one, 16(11), e0259093. X. T. Zhang et al. (2021).
A competitive ligand-binding assay for the detection of neutralizing antibodies against dostarlimab (TSR-042). AAPS Open, 7(1), 1-14. J. M. Chan et al. (2021).
Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer. Cancer Cell, 39(11), 1479-1496. F. Rüger et al. (2021).
Gold albumin Sandwich Structures for Enhanced Biosensing using Surface Plasmon Resonance. physica status solidi (a). doi.org/10.1002/pssa.202100029 L. He et al. (2021).
The effects of CD148 Q276P/R326Q polymorphisms in A431D epidermoid cancer cell proliferation and epidermal growth factor receptor signaling. Cancer Reports, e1566. B. Henrick et al. (2021).
Bifidobacteria-mediated immune system imprinting early in life. Cell 184(15), 3884-3898.e11.